News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Aegerion Pharmaceuticals, Inc. (AEGR)' Lomitapide Receives Orphan Drug Designation in Japan for the Treatment of Homozygous Familial Hypercholesterolemia


9/9/2013 9:02:27 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass., Sept. 9, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of novel, life-altering therapies for patients with debilitating, often fatal, rare diseases, announced today that the company has received orphan drug designation from Japan's Ministry of Labour, Health and Welfare for lomitapide for the treatment of homozygous familial hypercholesterolemia (HoFH).

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES